PHAT 16.00 Phathom Pharmaceuticals, Inc.

⇒

Stock List ⇒ Phathom Pharmaceuticals, Inc.

Range:	6.065-19.71	Vol Avg:	958215	Last Div:	0	Changes:	-0.62
Beta:	0.71	Cap:	1.03B	Currency:	USD	Exchange:	NASDAQ
Sector:	Healthcare			IPO:	Fri Oct 25 2019	Empoloyees:	452
CUSIP:	71722W107	CIK:	0001783183	ISIN:	US71722W1071	Country:	US
CEO:	Ms. Terrie J. Curran			Website:	https://www.phathompharma.com

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Stock Details

PHAT 12

Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs

Paul Choi·Thu Aug 08 2024

Goldman Sachs

PHAT 28

H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)

Matthew Caufield·Fri Jul 19 2024

H.C. Wainwright

PHAT 16.00 Phathom Pharmaceuticals, Inc.

Stock Details

PHAT 12

PHAT 28

Про сайт

Новини маркету

Ринки

Найкращі для покупки